Many obese people with type 2 diabetes develop non-alcoholic fatty liver disease, which may progress to liver fibrosis. EndoBarrier gastrointestinal liner is an innovative interventional treatment option for type 2 diabetic patients, which could affect diabetes associated liver disease.
Press Releases
2/13
1/3
GI Dynamics Appoints Vice President of Clinical and Regulatory Affairs
BOSTON and SYDNEY — 4 January 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing...
1/1